Financhill
Sell
49

PBYI Quote, Financials, Valuation and Earnings

Last price:
$3.32
Seasonality move :
-5.1%
Day range:
$3.29 - $3.46
52-week range:
$2.23 - $6.06
Dividend yield:
0%
P/E ratio:
5.44x
P/S ratio:
0.70x
P/B ratio:
1.79x
Volume:
265.7K
Avg. volume:
425.6K
1-year change:
-36.4%
Market cap:
$164.7M
Revenue:
$230.5M
EPS (TTM):
$0.61

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PBYI
Puma Biotechnology
$52.5M $0.14 1.79% -44% $4.33
BMY
Bristol-Myers Squibb
$11.3B $1.70 -9.23% 68.68% $61.24
JNJ
Johnson & Johnson
$22.4B $2.01 1.23% 96.75% $169.07
PDEX
Pro-Dex
$13.8M $0.38 23.84% 147.37% $54.00
SPRO
Spero Therapeutics
$6.2M -$0.31 -100% -505.55% $5.00
VNDA
Vanda Pharmaceuticals
$52.3M -- -4.9% -- $12.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PBYI
Puma Biotechnology
$3.32 $4.33 $164.7M 5.44x $0.00 0% 0.70x
BMY
Bristol-Myers Squibb
$59.01 $61.24 $119.7B -- $0.62 4.1% 2.48x
JNJ
Johnson & Johnson
$162.81 $169.07 $392.3B 28.12x $1.24 3.05% 4.45x
PDEX
Pro-Dex
$49.66 $54.00 $161.9M 24.83x $0.00 0% 2.77x
SPRO
Spero Therapeutics
$0.78 $5.00 $42.7M 9.78x $0.00 0% 0.47x
VNDA
Vanda Pharmaceuticals
$4.98 $12.67 $290.4M -- $0.00 0% 1.46x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PBYI
Puma Biotechnology
42.12% -1.261 44.77% 1.38x
BMY
Bristol-Myers Squibb
75.24% 1.206 44.34% 1.06x
JNJ
Johnson & Johnson
33.88% 0.530 10.52% 0.86x
PDEX
Pro-Dex
33.99% 3.333 10.75% 1.35x
SPRO
Spero Therapeutics
-- 1.066 -- 2.64x
VNDA
Vanda Pharmaceuticals
-- -0.270 -- 4.22x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PBYI
Puma Biotechnology
$45.2M $13.4M 20.19% 47.89% 25.15% $15.6M
BMY
Bristol-Myers Squibb
$7.5B $510M -13.01% -46.27% 5.44% $4.1B
JNJ
Johnson & Johnson
$15.4B $3.8B 13.3% 19.98% 17.87% $4.8B
PDEX
Pro-Dex
$5.1M $2.7M 15.21% 21.59% 16.61% -$4.7M
SPRO
Spero Therapeutics
-- -$18.6M 4.36% 4.36% -237.79% $12.8M
VNDA
Vanda Pharmaceuticals
$50.6M -$10.3M -3.49% -3.49% -19.33% -$2M

Puma Biotechnology vs. Competitors

  • Which has Higher Returns PBYI or BMY?

    Bristol-Myers Squibb has a net margin of 32.68% compared to Puma Biotechnology's net margin of 0.58%. Puma Biotechnology's return on equity of 47.89% beat Bristol-Myers Squibb's return on equity of -46.27%.

    Company Gross Margin Earnings Per Share Invested Capital
    PBYI
    Puma Biotechnology
    76.44% $0.39 $159.2M
    BMY
    Bristol-Myers Squibb
    61.01% $0.04 $66B
  • What do Analysts Say About PBYI or BMY?

    Puma Biotechnology has a consensus price target of $4.33, signalling upside risk potential of 30.52%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $61.24 which suggests that it could grow by 3.79%. Given that Puma Biotechnology has higher upside potential than Bristol-Myers Squibb, analysts believe Puma Biotechnology is more attractive than Bristol-Myers Squibb.

    Company Buy Ratings Hold Ratings Sell Ratings
    PBYI
    Puma Biotechnology
    0 1 0
    BMY
    Bristol-Myers Squibb
    4 18 1
  • Is PBYI or BMY More Risky?

    Puma Biotechnology has a beta of 1.334, which suggesting that the stock is 33.42% more volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.435, suggesting its less volatile than the S&P 500 by 56.528%.

  • Which is a Better Dividend Stock PBYI or BMY?

    Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 4.1% to investors and pays a quarterly dividend of $0.62 per share. Puma Biotechnology pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

  • Which has Better Financial Ratios PBYI or BMY?

    Puma Biotechnology quarterly revenues are $59.1M, which are smaller than Bristol-Myers Squibb quarterly revenues of $12.3B. Puma Biotechnology's net income of $19.3M is lower than Bristol-Myers Squibb's net income of $72M. Notably, Puma Biotechnology's price-to-earnings ratio is 5.44x while Bristol-Myers Squibb's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.70x versus 2.48x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PBYI
    Puma Biotechnology
    0.70x 5.44x $59.1M $19.3M
    BMY
    Bristol-Myers Squibb
    2.48x -- $12.3B $72M
  • Which has Higher Returns PBYI or JNJ?

    Johnson & Johnson has a net margin of 32.68% compared to Puma Biotechnology's net margin of 15.24%. Puma Biotechnology's return on equity of 47.89% beat Johnson & Johnson's return on equity of 19.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    PBYI
    Puma Biotechnology
    76.44% $0.39 $159.2M
    JNJ
    Johnson & Johnson
    68.35% $1.41 $108.1B
  • What do Analysts Say About PBYI or JNJ?

    Puma Biotechnology has a consensus price target of $4.33, signalling upside risk potential of 30.52%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.84%. Given that Puma Biotechnology has higher upside potential than Johnson & Johnson, analysts believe Puma Biotechnology is more attractive than Johnson & Johnson.

    Company Buy Ratings Hold Ratings Sell Ratings
    PBYI
    Puma Biotechnology
    0 1 0
    JNJ
    Johnson & Johnson
    7 13 0
  • Is PBYI or JNJ More Risky?

    Puma Biotechnology has a beta of 1.334, which suggesting that the stock is 33.42% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

  • Which is a Better Dividend Stock PBYI or JNJ?

    Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.24 per share. Puma Biotechnology pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PBYI or JNJ?

    Puma Biotechnology quarterly revenues are $59.1M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Puma Biotechnology's net income of $19.3M is lower than Johnson & Johnson's net income of $3.4B. Notably, Puma Biotechnology's price-to-earnings ratio is 5.44x while Johnson & Johnson's PE ratio is 28.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.70x versus 4.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PBYI
    Puma Biotechnology
    0.70x 5.44x $59.1M $19.3M
    JNJ
    Johnson & Johnson
    4.45x 28.12x $22.5B $3.4B
  • Which has Higher Returns PBYI or PDEX?

    Pro-Dex has a net margin of 32.68% compared to Puma Biotechnology's net margin of 12.15%. Puma Biotechnology's return on equity of 47.89% beat Pro-Dex's return on equity of 21.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    PBYI
    Puma Biotechnology
    76.44% $0.39 $159.2M
    PDEX
    Pro-Dex
    30.2% $0.61 $48.2M
  • What do Analysts Say About PBYI or PDEX?

    Puma Biotechnology has a consensus price target of $4.33, signalling upside risk potential of 30.52%. On the other hand Pro-Dex has an analysts' consensus of $54.00 which suggests that it could grow by 8.74%. Given that Puma Biotechnology has higher upside potential than Pro-Dex, analysts believe Puma Biotechnology is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    PBYI
    Puma Biotechnology
    0 1 0
    PDEX
    Pro-Dex
    1 0 0
  • Is PBYI or PDEX More Risky?

    Puma Biotechnology has a beta of 1.334, which suggesting that the stock is 33.42% more volatile than S&P 500. In comparison Pro-Dex has a beta of 0.682, suggesting its less volatile than the S&P 500 by 31.755%.

  • Which is a Better Dividend Stock PBYI or PDEX?

    Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PBYI or PDEX?

    Puma Biotechnology quarterly revenues are $59.1M, which are larger than Pro-Dex quarterly revenues of $16.8M. Puma Biotechnology's net income of $19.3M is higher than Pro-Dex's net income of $2M. Notably, Puma Biotechnology's price-to-earnings ratio is 5.44x while Pro-Dex's PE ratio is 24.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.70x versus 2.77x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PBYI
    Puma Biotechnology
    0.70x 5.44x $59.1M $19.3M
    PDEX
    Pro-Dex
    2.77x 24.83x $16.8M $2M
  • Which has Higher Returns PBYI or SPRO?

    Spero Therapeutics has a net margin of 32.68% compared to Puma Biotechnology's net margin of -219.3%. Puma Biotechnology's return on equity of 47.89% beat Spero Therapeutics's return on equity of 4.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    PBYI
    Puma Biotechnology
    76.44% $0.39 $159.2M
    SPRO
    Spero Therapeutics
    -- -$0.32 $65.5M
  • What do Analysts Say About PBYI or SPRO?

    Puma Biotechnology has a consensus price target of $4.33, signalling upside risk potential of 30.52%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 539.06%. Given that Spero Therapeutics has higher upside potential than Puma Biotechnology, analysts believe Spero Therapeutics is more attractive than Puma Biotechnology.

    Company Buy Ratings Hold Ratings Sell Ratings
    PBYI
    Puma Biotechnology
    0 1 0
    SPRO
    Spero Therapeutics
    0 2 0
  • Is PBYI or SPRO More Risky?

    Puma Biotechnology has a beta of 1.334, which suggesting that the stock is 33.42% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.497%.

  • Which is a Better Dividend Stock PBYI or SPRO?

    Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PBYI or SPRO?

    Puma Biotechnology quarterly revenues are $59.1M, which are larger than Spero Therapeutics quarterly revenues of $7.8M. Puma Biotechnology's net income of $19.3M is higher than Spero Therapeutics's net income of -$17.1M. Notably, Puma Biotechnology's price-to-earnings ratio is 5.44x while Spero Therapeutics's PE ratio is 9.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.70x versus 0.47x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PBYI
    Puma Biotechnology
    0.70x 5.44x $59.1M $19.3M
    SPRO
    Spero Therapeutics
    0.47x 9.78x $7.8M -$17.1M
  • Which has Higher Returns PBYI or VNDA?

    Vanda Pharmaceuticals has a net margin of 32.68% compared to Puma Biotechnology's net margin of -9.24%. Puma Biotechnology's return on equity of 47.89% beat Vanda Pharmaceuticals's return on equity of -3.49%.

    Company Gross Margin Earnings Per Share Invested Capital
    PBYI
    Puma Biotechnology
    76.44% $0.39 $159.2M
    VNDA
    Vanda Pharmaceuticals
    95.13% -$0.08 $538.5M
  • What do Analysts Say About PBYI or VNDA?

    Puma Biotechnology has a consensus price target of $4.33, signalling upside risk potential of 30.52%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 154.35%. Given that Vanda Pharmaceuticals has higher upside potential than Puma Biotechnology, analysts believe Vanda Pharmaceuticals is more attractive than Puma Biotechnology.

    Company Buy Ratings Hold Ratings Sell Ratings
    PBYI
    Puma Biotechnology
    0 1 0
    VNDA
    Vanda Pharmaceuticals
    1 1 0
  • Is PBYI or VNDA More Risky?

    Puma Biotechnology has a beta of 1.334, which suggesting that the stock is 33.42% more volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.079%.

  • Which is a Better Dividend Stock PBYI or VNDA?

    Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PBYI or VNDA?

    Puma Biotechnology quarterly revenues are $59.1M, which are larger than Vanda Pharmaceuticals quarterly revenues of $53.2M. Puma Biotechnology's net income of $19.3M is higher than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Puma Biotechnology's price-to-earnings ratio is 5.44x while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.70x versus 1.46x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PBYI
    Puma Biotechnology
    0.70x 5.44x $59.1M $19.3M
    VNDA
    Vanda Pharmaceuticals
    1.46x -- $53.2M -$4.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock